News articles about Zymeworks (NASDAQ:ZYME) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Zymeworks earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.972286492669 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Zymeworks (NASDAQ:ZYME) traded down 1.67% on Tuesday, hitting $8.25. The stock had a trading volume of 7,878 shares. The stock has a 50-day moving average of $8.44 and a 200-day moving average of $9.09. Zymeworks has a one year low of $6.25 and a one year high of $14.25. The company’s market cap is $209.05 million.
ZYME has been the subject of a number of recent analyst reports. Zacks Investment Research raised Zymeworks from a “sell” rating to a “hold” rating in a report on Thursday, October 12th. Scotiabank downgraded Zymeworks from an “overweight” rating to an “underweight” rating in a report on Thursday, September 7th. Cormark reaffirmed a “buy” rating on shares of Zymeworks in a research note on Saturday, September 30th. Finally, Barclays PLC reaffirmed an “underweight” rating and set a $8.00 price target on shares of Zymeworks in a research note on Thursday, September 7th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $16.00.
TRADEMARK VIOLATION WARNING: “Zymeworks (ZYME) Earning Somewhat Positive News Coverage, Analysis Finds” was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.com-unik.info/2017/10/31/zymeworks-zyme-earning-somewhat-positive-news-coverage-analysis-finds.html.
Zymeworks Company Profile
Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins.
What are top analysts saying about Zymeworks Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zymeworks Inc and related companies.